Clinical Safety of Chemotherapy for Elderly Cancer Patients Complicated with Hypertension |
Qian, Ya-Dong
(Deaprtment of Internal Medicine, Gao Gang People Hospital)
Xu, Xu (Deaprtment of Internal Medicine, Gao Gang People Hospital) Wang, Lin (Deaprtment of Internal Medicine, Gao Gang People Hospital) Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) |
1 | Cao Y, Tan A, Gao F, et al (2009). A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis, 24, 677-85. DOI |
2 | Choi KH, Park SM, Lee K, et al (2013). Prevalence, awareness, control, and treatment of hypertension and diabetes in Korean cancer survivors: a cross-sectional analysis of the fourth and fifth Korea national health and nutrition examination surveys. Asian Pac J Cancer Prev, 14, 7685-92. 과학기술학회마을 DOI |
3 | Daher IN, Yeh ET (2008). Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med, 5, 797-805. DOI |
4 | Havlik RJ, Yancik R, Long S, Ries L, Edwards B (1994). The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer, 74, 2101-6. DOI ScienceOn |
5 | Izzedine H, Ederhy S, Goldwasser F, et al (2009). Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol, 20, 807-15. DOI ScienceOn |
6 | Jain M, Townsend RR (2007). Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep, 9, 320-8. DOI ScienceOn |
7 | Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh JWW (1998). Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer, 21, 105-13. DOI ScienceOn |
8 | Janssen-Heijnen MLG, Smulders S, Lemmens VEPP, et al (2004). Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax, 59, 602-7. DOI |
9 | Ko C, Chaudhry S (2002). The need for a multidisciplinary approach to cancer care. J Surg Res, 105, 53-7. DOI ScienceOn |
10 | Lopez-Encuentra A (2002). Comorbidity in operable lung cancer: a multicenter descriptive study on 2992 patients. Lung Cancer, 35, 263-9. DOI |
11 | Pereira A, Garmendia ML, Alvarado ME, Albala C (2012). Hypertension and the risk of breast cancer in Chilean women: a case-control study. Asian Pac J Cancer Prev, 13, 5829-34. 과학기술학회마을 DOI |
12 | Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL., Jr (2004). Prognostic importance of comorbidity in a hospitalbased cancer registry. JAMA, 291 2441-7. DOI |
13 | Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010). Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens, 23, 460-8. DOI ScienceOn |
14 | Satariano WA, Ragland DR (1994). The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med, 120, 104-10. DOI ScienceOn |
15 | Smith AW, Reeve BB, Bellizzi KM, et al (2008). Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev, 29, 41-56. |
16 | Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005). Comorbidity and survival disparities among black and white patients with breast cancer. JAMA, 294, 1765-72. DOI ScienceOn |
17 | Townsend RR (2006). Hypertension and cancer chemotherapies. In: Mohler ER, Townsend RR, editors. Advanced Therapy in Hypertension and Vascular Disease. Toronto, Canada: BC Decker; 2006. pp. 502-7. |
18 | Yeh ETH (2006). Cardiotoxicity induced by chemotherapy and antibody therapy. Ann Rev Med, 57, 485-98. DOI |
19 | Yancik R, Wesley MN, Ries LA, et al (1998). Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer, 82, 2123-34. DOI ScienceOn |
20 | Yancik R, Wesley MN, Ries LAG, et al (2001). Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA, 285, 885-92. DOI ScienceOn |